Marqibo

What is Marqibo?

Marqibo is a treatment for cancer that blocks the growth of cancerous cells and reduces their spread throughout the body. Marqibo is used to treat a form of blood cancer referred to as Philadelphia chronic lymphoblastic leukemia (ALL). It is typically administered after at least two other chemotherapy drugs have been tried with no success. Marqibo is prescribed after at least two other treatments for cancer did not work or ended up failing.

Warnings

It is not recommended to take Marqibo in the event that you suffer from Charcot-Marie-Tooth syndrome or other disorders that result in damage to your myelin (the protective cover for nerves in your spinal cord and brain).

Before you take this drug

You shouldn't take Marqibo if you're sensitive to vincristine liposomes or if you suffer from Charcot-Marie-Tooth syndrome or other disorders that result in damage to the myelin (the protective cover for nerves that run through the spinal cord and brain). To ensure that Marqibo is appropriate for you, consult your physician if you suffer from:

• Liver disease.
• A nerve-muscle disorder like myasthenia gravis, ALS (Lou Gehrig's disease), multiple sclerosis, and muscle dystrophy.
• An obstruction in the bowel known as "paralytic ileus.
• Peripheral vascular disorder, such as Raynaud's syndrome.

Vincristine liposomes can cause harm to a baby who is not yet born. Use effective birth control to stop pregnancy and notify your physician if you are pregnant. You shouldn't breastfeed when using Marqibo. If you're using an infant pump during this period, dispose of the milk you have collected. Don't feed it to your child. Follow the advice of your physician on when you should begin breastfeeding once your treatment has ended.

How to take Marqibo?

Marqibo is administered as an infusion to the vein, typically every week. The doctor will provide the injection. Marqibo needs to be administered slowly, and infusions can take at least an hour to be completed. Inform your doctor if you feel any pain, burning, or swelling near the needle of your IV when Marqibo has been injected. Marqibo may cause extreme constipation. It is possible to receive medication to avoid constipation while you take Marqibo. Take all medications as directed by your physician. Be sure to avoid constipation by eating vegetables, fruits, and other foods rich in fiber. Make sure you drink plenty of fluids. Marqibo may lower blood cell counts. Your blood needs to be checked frequently. Your treatment for cancer could be delayed based on the results.

Details on dosage

Marqibo Adult Dose for Malignant Disease

The dose suggested by the manufacturer is 1.4 mg/m2 IV for one minute, once per week.
Comments: This is the manufacturer's recommended dose. It is not a definitive reference. The protocol of the institution should be reviewed.
The dosage of this medication will depend on the particular reason for its use and whether or not other cytotoxic agents are administered in conjunction with it. The subsequent doses can be determined by the hematologic and clinical reactions that the person is experiencing.
Use for: acute leukemia (This drug has also been proven to be effective in conjunction with other agents for oncolytics in Hodgkin's malignant lymphomas and non-Hodgkin's Hodgkin's such as rhabdomyosarcomas, neuroblastomas, and Wilms" tumors.)

Usual Adult Dose of Marqibo for Solid Tumors

Manufacturer recommended dose: 1.4 mg/m2 IV for 1 minute every week
Comments: This is the manufacturer's recommended dose. This is only a general guideline. The protocol of the institution should be reviewed.
The dosage of this medication will depend on the particular purpose for its use and whether any other cytotoxic agents are administered in conjunction with it. The subsequent doses can depend on the hematologic and clinical responses of the individual to treatment.
Use for: acute leukemia (This drug is also proven to be effective in conjunction with other agents for oncolytics in Hodgkin's disease, non-Hodgkin's malignant lymphomas, neuroblastoma, rhabdomyosarcoma, and Wilms" tumor.)

Usual Pediatric Dose of Marqibo for Malignant Disease

Age less than 18 in addition to or less than 10kg:
Initial dosage: 0.05 mg/kg IV over 1 minute, once per week
Maximum dose: 2 mg/m2 intravenously every week
Ages less than 18 and over 10 kg: 1–2 mg/m2 IV for one minute every week
Comments: The dose listed is the manufacturer's suggestion. It is not a definitive guideline. It is recommended to consult the institutional protocol.
The dosage of this medication will depend on the particular reason for its use and if other drugs that cause cytotoxicity are also administered. The subsequent doses can be determined by clinical and hematologic responses to the individual's treatment.
Use for: acute leukemia (This drug is also proven to be effective in conjunction with other agents for oncolytics in Hodgkin's malignant lymphomas and non-Hodgkin's Hodgkin's such as rhabdomyosarcomas, neuroblastomas, and Wilms tumors.)

Usual Pediatric Dose of Marqibo for Solid Tumors:

Age less than 18 and less than 10 kg:
Initial dosage: 0.05 mg/kg IV over one minute every week
Maximum dosage: 2 mg/m2 IV for one minute, once per week.
less than 18 years old and more than 10 kg, between 1 and 2 mg/m2 intravenous in 1 minute, once per week
Comments: This dose is the manufacturer's suggestion. This is merely a set of guidelines. It is recommended to consult the institutional protocol.
The dose of this drug will depend on the particular reason for its use and whether any other cytotoxic agents are administered in conjunction with it. Doses to follow can be determined based on the hematologic and clinical response that the person is experiencing.
Use for: acute leukemia This drug is also proven to be effective in conjunction with other agents for oncolytics in Hodgkin's malignant lymphomas, non-Hodgkin's neuroblastoma, rhabdomyosarcoma, and Wilms tumor.

What happens if I miss a dose?

Contact your doctor for advice. If you do not make an appointment to receive an appointment for Marqibo injection,

What happens if I overdose?

Get medical attention in an emergency or contact the Poison Help line toll-free at 1-800-222-1222.

What should be avoided?

Avoid driving and other hazardous activities until you are aware of what the impact of Marqibo could be on your health. The way you react could be impaired. Beware of those with illnesses or suffering from infections. Inform your doctor immediately when you begin to show symptoms of an infection.

 Side effects of Marqibo

See a doctor immediately. Get medical attention immediately if you show symptoms of an allergic reaction to Marqibo, such as itching, breathing difficulties, or swelling of your lips, face, and tongue.

See your doctor right away. If you are suffering from:

• Extreme constipation and stomach pains; bloating.
• Severe ongoing nausea, vomiting, or diarrhea.
• The sensation of tingling or numbness, as well as burning or numbness in your feet or hands.
• Severe tiredness.
• Lower blood-cell counts, such as chills, fever, and cough. Mouth sores, skin sores, easy bleeding, unusual bleeding, pale skin, cold hands and feet, being lightheaded or sluggish.
• Symptoms of a tumor cell's breakdown: weakening, fatigue, muscle cramps, nausea, vomiting, diarrhea, a fast and moderate heartbeat, as well as tingling in your feet, hands, and around the mouth.

Common Marqibo side effects can be:

• High fever, low blood cell count.
• Tiredness.
• Numbness, tingling.
• Diarrhea, constipation.
• Vomiting, or loss of appetite, nausea.
• Sleep problems (insomnia).

This isn't a complete list of all the side effects. Others could happen. Consult your physician for advice regarding medical effects. You can report any side effects to the FDA at 1-800-FDA-1088.

Interaction with other drugs

Inform your doctor about all the medications you take. Numerous drugs may interfere with Marqibo, particularly:

• John's wort.
• Is an antibiotic: clarithromycin, rifabutin, rifampin, therifapentine, and telithromycin.
• Antifungal medicine (itraconazole, ketoconazole).
• Antiviral medicine for treating hepatitis C as well as HIV/AIDS: efavirenz, indinavir, and nelfinavir; nevirapine; ritonavir; saquinavir; tipranavir; telaprevir.
• Cancer medicine: apalutamide, enzalutamide, and mitotane.
• Amiodarone, dronedarone, quinidine, ranolazine, and verapamil are examples of blood pressure or heart medicine.
• Medicine to stop rejection of organ transplants; the risk of rejection: closporine, tacrolimus.
• Seizure medicine: carbamazepine, oxcarbazepine, phenytoin, primidone.
• Steroid medicine: dexamethasone, prednison.

This isn't a complete list, and other medications may interfere with the vincristine liposome. This includes both over-the-counter and prescription drugs, vitamins, and herbal products. There are many possible interactions between drugs. are included here.